Key Trials at ASCO 2023 Highlight Role of Perioperative Treatment Approaches in NSCLC

Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.

Related Keywords

Ireland ,Dublin ,Jarushka Naidoo ,Heather Wakelee ,Stanford Health ,European Medicines Agency ,Royal College Of Surgeons Ireland Cancer Centre ,News Network ,Royal College ,Surgeons Ireland Cancer Centre ,Beaumont Hospital ,Treating Field ,Amivantamab Plus Lazertinib ,Patients With Egfr Mutated Non Small Cell Lung Cancer ,Nct04077463 ,Pasco ,Nsclc ,Mbbch ,Checkmate 816 ,Keynote 617 ,Daura ,Checkmate 9la ,Lunar ,Artemide 01 ,Keynote 789 ,